AcelRx to Host Third Quarter 2020 Financial Results Call and Webcast on Thursday, November 5, 2020

Rhea-AI Summary

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) will release its third quarter financial results on November 5, 2020, after market close. A live webcast and conference call will take place at 4:30 p.m. ET to discuss these results and provide business updates. The conference call can be accessed by dialing specific numbers for domestic, Canadian, and international callers. AcelRx specializes in developing innovative therapies for medically supervised settings and has one FDA-approved product, DSUVIA®, and another candidate, Zalviso®, currently in development.

Positive

• AcelRx has an FDA-approved product, DSUVIA®, in the U.S. for acute pain management.
• The company is developing Zalviso®, a patient-controlled analgesia system, approved in Europe.

Negative

• None.

REDWOOD CITY, Calif., Oct. 29, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release third quarter financial results after market close on Thursday, November 5, 2020. AcelRx management will host a live webcast and conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on November 5, 2020 to discuss the financial results and provide an update on the company's business.

The webcast is accessible by visiting the Investors page of the company's website at www.acelrx.com and clicking on the webcast link on the Investors home page. The webcast will be accompanied by a slide presentation.  A webcast replay will be available on the AcelRx website for 90 days following the call by visiting the Investor page of the company's website at www.acelrx.com.

Investors who wish to participate in the conference call may do so by dialing (866) 361-2335 for domestic callers, (855) 669-9657 for Canadian callers, or (412) 902-4204 for international callers.

About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The Company has one approved product in the U.S., DSUVIA®(sufentanil sublingual tablet, 30 mcg), known as DZUVEO™ in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and one product candidate, Zalviso®(sufentanil sublingual tablet system, SST system, 15 mcg), being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings. DZUVEO and Zalviso are both approved products in Europe. Zalviso is an investigational drug and not approved in the U.S. For additional information about AcelRx, please visit www.acelrx.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/acelrx-to-host-third-quarter-2020-financial-results-call-and-webcast-on-thursday-november-5-2020-301163381.html

SOURCE AcelRx Pharmaceuticals, Inc.

FAQ

When will AcelRx release its third quarter financial results for 2020?

AcelRx will release its third quarter financial results on November 5, 2020, after market close.

What is the purpose of AcelRx's conference call on November 5, 2020?

The conference call will discuss the third quarter financial results and provide business updates.

How can I access AcelRx's conference call on November 5, 2020?

Investors can participate by dialing specific numbers for domestic or international callers.

What products does AcelRx have in its portfolio?

AcelRx has one approved product, DSUVIA®, and is developing Zalviso®, a patient-controlled analgesia system.

Is Zalviso® approved in the U.S.?

No, Zalviso® is currently an investigational drug and is not approved in the U.S.